MCID: BNR002
MIFTS: 49

Bone Resorption Disease

Categories: Bone diseases

Aliases & Classifications for Bone Resorption Disease

MalaCards integrated aliases for Bone Resorption Disease:

Name: Bone Resorption Disease 12 15
Bone Resorption 43

Classifications:



External Ids:

Disease Ontology 12 DOID:0080011
MeSH 43 D001862

Summaries for Bone Resorption Disease

Disease Ontology : 12 A bone remodeling disease that results in an abnormal decrease of bone density or mass.

MalaCards based summary : Bone Resorption Disease, also known as bone resorption, is related to osteopetrosis and multicentric carpotarsal osteolysis syndrome. An important gene associated with Bone Resorption Disease is BGLAP (Bone Gamma-Carboxyglutamate Protein), and among its related pathways/superpathways are Wnt Signaling Pathways: beta-Catenin-dependent Wnt Signaling and RANK Signaling in Osteoclasts. The drugs sodium fluoride and Polyestradiol phosphate have been mentioned in the context of this disorder. Affiliated tissues include bone, breast and bone marrow, and related phenotypes are cellular and craniofacial

Wikipedia : 74 Bone resorption is resorption of bone tissue, that is, the process by which osteoclasts break down the... more...

Related Diseases for Bone Resorption Disease

Diseases related to Bone Resorption Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 408)
# Related Disease Score Top Affiliating Genes
1 osteopetrosis 33.4 TNFSF11 TNFRSF11B LRP5 CTSK CALCA BGLAP
2 multicentric carpotarsal osteolysis syndrome 33.4 TNFSF11 TNFRSF11B BGLAP
3 pycnodysostosis 33.3 TNFSF11 SOST CTSK
4 bone giant cell tumor 33.2 TNFSF11 TNFRSF11B PTH CTSK CALCA ACP5
5 paget's disease of bone 33.1 VDR TNFSF11 TNFRSF11B SOST PTH CALCA
6 osteitis fibrosa 32.9 PTH CALCA BGLAP
7 paget disease of bone 5, juvenile-onset 32.9 TNFSF11 TNFRSF11B CALCA
8 glucocorticoid-induced osteoporosis 32.8 VDR TNFSF11 TNFRSF11B SOST RUNX2 PTH
9 periodontitis 32.2 VDR TNFSF11 TNFRSF11B RUNX2 CTSK BGLAP
10 mammary paget's disease 31.8 TNFSF11 TNFRSF11B PTH CTSK CALCA BGLAP
11 osteoporosis 31.8 VDR TNFSF11 TNFRSF11B SP7 SOST RUNX2
12 hyperparathyroidism 31.7 VDR TNFSF11 TNFRSF11B SOST PTH CALCA
13 bone remodeling disease 31.6 VDR TNFSF11 TNFRSF11B SP7 SOST RUNX2
14 giant cell tumor 31.6 TNFSF11 TNFRSF11B CTSK CALCA BGLAP ACP5
15 secondary hyperparathyroidism 31.5 VDR TNFRSF11B PTH CALCA BGLAP ACP5
16 osteogenic sarcoma 31.5 TNFSF11 TNFRSF11B SP7 RUNX2 PTH MIR140
17 rheumatoid arthritis 31.4 TNFSF11 TNFRSF11B PTH CTSK BGLAP ACP5
18 hypercalcemia, infantile, 1 31.4 VDR PTH CALCA
19 arthropathy 31.4 TNFSF11 TNFRSF11B IGF1
20 hyperthyroidism 31.4 PTH IGF1 CALCA BGLAP ACP5
21 synovitis 31.4 TNFSF11 TNFRSF11B ACP5
22 primary hyperparathyroidism 31.3 VDR TNFSF11 TNFRSF11B SOST PTH IGF1
23 periodontitis, chronic 31.3 TNFSF11 TNFRSF11B
24 osteomalacia 31.3 VDR TNFSF11 PTH CALCA BGLAP
25 myeloma, multiple 31.3 TNFSF11 TNFRSF11B SOST RUNX2 PTH MIR335
26 osteomyelitis 31.3 TNFSF11 CTSK CALCA BMP2 ACP5
27 idiopathic hypercalciuria 31.2 VDR TNFSF11 BGLAP
28 osteonecrosis 31.2 TNFSF11 TNFRSF11B RUNX2 PTH NFATC1 LRP5
29 bone inflammation disease 31.2 TNFSF11 TNFRSF11B MIR140 ACP5
30 ankylosis 31.2 TNFRSF11B SP7 RUNX2 BMP2 BGLAP
31 root resorption 31.2 VDR TNFSF11 TNFRSF11B RUNX2 CTSK CALCA
32 renal osteodystrophy 31.1 VDR TNFSF11 TNFRSF11B SOST PTH CALCA
33 hypervitaminosis d 31.1 VDR PTH CALCA
34 spondyloarthropathy 1 31.1 TNFSF11 TNFRSF11B PTH BGLAP
35 hypoparathyroidism 31.1 VDR PTH CALCA BGLAP
36 exostosis 31.0 CALCA BMP2 BGLAP
37 periapical periodontitis 31.0 TNFSF11 TNFRSF11B NFATC1 CTSK ACP5
38 hemiplegia 31.0 CALCA BGLAP ACP5
39 otosclerosis 31.0 VDR TNFSF11 TNFRSF11B CALCA BMP2
40 hypophosphatemia 30.9 VDR PTH BGLAP
41 nephrolithiasis, calcium oxalate 30.8 VDR PTH CALCA BGLAP
42 bone cancer 30.8 VDR TNFSF11 TNFRSF11B MIR335 MIR214 MIR140
43 endosteal hyperostosis, autosomal dominant 30.8 TNFSF11 TNFRSF11B SP7 SOST PTH NFATC1
44 uremia 30.7 VDR TNFRSF11B PTH
45 osteopetrosis, autosomal recessive 2 30.7 TNFSF11 NFATC1 ACP5
46 brittle bone disorder 30.7 TNFSF11 TNFRSF11B SP7 SOST RUNX2 PTH
47 hemophilic arthropathy 30.7 TNFSF11 TNFRSF11B
48 scoliosis 30.7 VDR TNFSF11 TNFRSF11B RUNX2 IGF1 BGLAP
49 fibrous dysplasia 30.7 RUNX2 IGF1 CALCA BGLAP
50 sclerosteosis 30.7 VDR TNFSF11 TNFRSF11B SP7 SOST RUNX2

Graphical network of the top 20 diseases related to Bone Resorption Disease:



Diseases related to Bone Resorption Disease

Symptoms & Phenotypes for Bone Resorption Disease

MGI Mouse Phenotypes related to Bone Resorption Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10 BMP2 CTSK IGF1 LRP5 NFATC1 PTH
2 craniofacial MP:0005382 9.81 BMP2 CTSK LRP5 NFATC1 PTH RUNX2
3 limbs/digits/tail MP:0005371 9.73 BMP2 CTSK IGF1 LRP5 NFATC1 PTH
4 skeleton MP:0005390 9.4 BMP2 CTSK IGF1 LRP5 NFATC1 PTH

Drugs & Therapeutics for Bone Resorption Disease

Drugs for Bone Resorption Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 345)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 sodium fluoride Approved Phase 4 7681-49-4
2
Polyestradiol phosphate Approved Phase 4 28014-46-2
3
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
4
Pamidronate Approved Phase 4 40391-99-9 4674
5
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
6
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
7
Atorvastatin Approved Phase 4 134523-00-5 60823
8
Lovastatin Approved, Investigational Phase 4 75330-75-5 53232
9
Liraglutide Approved Phase 4 204656-20-2 44147092
10
Simvastatin Approved Phase 4 79902-63-9 54454
11
Curcumin Approved, Experimental, Investigational Phase 4 458-37-7 969516
12
Edetic Acid Approved, Vet_approved Phase 4 62-33-9, 60-00-4 6049
13
Pentetic acid Approved Phase 4 67-43-6
14
Turmeric Approved, Experimental, Investigational Phase 4
15
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
16
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
17
Potassium citrate Approved, Investigational, Vet_approved Phase 4
18
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850
19
Adalimumab Approved Phase 4 331731-18-1 16219006
20
Sodium citrate Approved, Investigational Phase 4 68-04-2
21
Cinacalcet Approved Phase 4 226256-56-0 156419
22
Salmon Calcitonin Approved, Investigational Phase 4 47931-85-1 16129616
23
Denosumab Approved Phase 4 615258-40-7
24
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
25
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
26
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
27
Clobetasol Approved, Experimental, Investigational Phase 4 25122-46-7, 25122-41-2 32798 5311051
28
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
29
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
30
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
31
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
32
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
33
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
34
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
35
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
36
Calcitonin gene-related peptide Investigational Phase 4 83652-28-2
37
gastric inhibitory polypeptide Investigational Phase 4 100040-31-1
38 Listerine Phase 4
39 calcium channel blockers Phase 4
40 Ibandronic Acid Phase 4
41 Selective Estrogen Receptor Modulators Phase 4
42 Raloxifene Hydrochloride Phase 4
43 Estrogen Receptor Modulators Phase 4
44 Estrogen Receptor Antagonists Phase 4
45 Estrogen Antagonists Phase 4
46 Anti-Retroviral Agents Phase 4
47 Estradiol 17 beta-cypionate Phase 4
48 Estradiol 3-benzoate Phase 4
49 Contraceptive Agents Phase 4
50 Respiratory System Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 478)
# Name Status NCT ID Phase Drugs
1 Prospective, Non-Randomised, Non-Comparative Multicentric Investigation of the Functional and Radiological Result and Subjective Patient Outcome After Implantation of a Hip Resurfacing Endoprosthesis (Birmingham Hip Resurfacing) Unknown status NCT00180206 Phase 4
2 Clinical and Microbiological Effects of an Essential Oils Solution Used as an Adjunct to Daily Oral Hygiene Practices in Chronic Periodontitis Patients in Supportive Care Unknown status NCT01195493 Phase 4
3 Effects of Sitagliptin On Markers of Bone Turnover in Patients With Type 2 Diabetes Unknown status NCT00732121 Phase 4 Sitagliptin;Placebo
4 Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption Completed NCT01750086 Phase 4 Teriparatide 40-mcg subcutaneous injection;Denosumab Injection;Alendronate Oral Tablet
5 The Efficacy of Denosumab in Decreasing Periprosthetic Bone Loss in Patients With Total Knee Arthroplasty: A Randomised, Double Blind, Placebo Controlled Clinical Trial Completed NCT02760979 Phase 4 Denosumab;Placebo
6 A Randomized, Double-blind, Placebo-controlled Study to Determine Time to Onset of Suppression of the Bone Resorption Marker sCTX With Once Monthly Ibandronate in the Treatment of Postmenopausal Osteoporosis Completed NCT00303485 Phase 4 Placebo;Vitamin D and calcium supplementation;ibandronate [Bonviva/Boniva]
7 Periprosthetic Bone Mineral Changes Around Stemless and Stemmed Cementless Femoral Components Completed NCT00957970 Phase 4
8 Efficacy and Safety of Alendronate in Chinese Children or Adolescents With Osteogenesis Imperfecta: an Age Stratified Prospective Study Completed NCT02303873 Phase 4 Alendronate
9 An Open, Prospective, Multi-center Study to Evaluate Bone Loss, the Survival Rate of SPI Implant System and Implant Stability Over a 24 Months, in Patients With Tooth Loss Requiring up to 4 Implants, in Staged Loading Protocol. Completed NCT02367261 Phase 4
10 Impact of NTx Point of Care (POC) Device on Patient Satisfication With Actonel 35mg Once a Seek Treatment a Multicenter Prospective Open Label Randomized Controlled Community Practice-based Study Completed NCT00549068 Phase 4 Risedronate Sodium (Actonel)
11 Short-Term Menatetrenone Therapy Increases Gamma-Carboxylation Of Osteocalcin With A Moderate Increase Of Bone Turnover In Postmenopausal Osteoporosis: A Randomized Prospective Study Completed NCT00548509 Phase 4 Menatetrenone (Vitamin K2)
12 A Multi-center Study to Evaluate Bone Loss, Survival Rate and Stability of ICE Implant System Over 24 Months, for Patients With Tooth Loss Requiring up to 4 Implants, in Staged Loading Protocol Completed NCT01960361 Phase 4
13 The Change of Bone Markers After Low Dose Alendronate in Postmenopausal Women Completed NCT00460057 Phase 4 Alendronate
14 Enhancing Osteoporosis Therapy: Can We Open the Anabolic Window? Completed NCT01166958 Phase 4 Teriparatide;Raloxifene
15 The Effect of Vitamin K Supplementation on Bone Health Indices in Adult Crohn's Disease Completed NCT01235325 Phase 4
16 Investigation of the Effects of Bisphosphonate on the Gingival Crevicular Fluid Levels of Sclerostin and the DKK-1 in Individuals With Postmenopausal Osteoporosis With Periodontal Changes Completed NCT04149405 Phase 4 bisphosphonate therapy
17 Do Aromatase Inhibitors (AIs) Decrease Intestinal Calcium Absorption? Completed NCT00766532 Phase 4 Aromatase Inhibitor
18 Effects of 1% Sodium Alendronate in Non Surgical Periodontal Therapy on Clinical and Tomographical Parameters: a Randomized Placebo Controlled 6-month Clinical Trial Completed NCT02470611 Phase 4 Sodium alendronate
19 Denosumab Counteracts Metabolic Bone Disease in Chronic Intestinal Failure Patients: A Randomized, Controlled Clinical Trial Completed NCT02853539 Phase 4 Denosumab
20 Effects of Rosiglitazone on Bone in Postmenopausal Diabetic Women Completed NCT00440375 Phase 4 Rosiglitazone
21 Phase IV Study Teriparatide and Antiresorptive Combination Treatment Subsequent to 9 Months of Teriparatide Monotherapy Completed NCT01535027 Phase 4 teriparatide;teriparatide and raloxifene;teriparatide and alendronate
22 "Comparative Evaluation Of The Efficacy Of Atorvastatin Gel As An Adjunct To Allografts In The Treatment Of Intrabony Defects" - A Clinico Radiological Study Completed NCT03009097 Phase 4 DFDBA with atorvastatin
23 A Randomized, Double-Blind, Placebo-Controlled Study of N-3 Fatty Acid on Plasma Triglyceride Levels in Hypertriglyceridemic HIV Patients Receiving Highly Active Antiretroviral Therapy Completed NCT00346697 Phase 4 Omega-3 fatty acid administration;Placebo
24 Osteopenia and Renal Osteodystrophy: Evaluation and Management Completed NCT00108394 Phase 4 pamidronate
25 The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function Completed NCT02473809 Phase 4 Liraglutide;Placebo
26 Curcumin-Simvastatin Release Profile in the Gingival Crevicular Fluid Following EDTA Root Surface Etching in the Surgical Treatment of Intrabony Periodontal Defects - A Biochemical and Clinical Study Completed NCT04044417 Phase 4 curcumin simvastatin paste;EDTA root conditioning
27 Socket Augmentation Using Different Platelet Concentrates, Atorvastatin Gel or Combination (Clinical and Histomorphometric Study) Completed NCT03231137 Phase 4 ATV gel
28 Socket Augmentation Using Atorvastatin With Or Without PRGF Derived Fibrin Scaffold (Clinical and Histomorphometric Study) Completed NCT03228771 Phase 4 PRGF/ATV;ATV gel
29 Local Minocycline to Reduce Future Inflammation and Bone Loss in Periodontal Maintenance Patients Completed NCT01647282 Phase 4 locally-applied minocycline HCl (1 mg)
30 The Study of Efficacy and Safety of Calcium Sensing Receptor in Chronic Dialysis Patients Completed NCT02056730 Phase 4 calcium sensing receptor agonist
31 Estrogen Dosing in Turner Syndrome:Pharmacology & Metabolism Completed NCT00837616 Phase 4 17 B estradiol orally;17 B estradiol
32 Denosumab in Primary Hyperparathyroidism Completed NCT01558115 Phase 4 Denosumab
33 The Effect Of The Bisphosphonate, Zoledronic Acid, On Bone Density In Liver Transplant Patients – A Prospective, Randomised, Controlled Clinical Trial Completed NCT00114556 Phase 4 zoledronic acid
34 A Randomized Placebo Controlled Double Blind Investigation of the Effects of Potassium Citrate on Bone Metabolism in Postmenopausal Osteopenia Completed NCT00357331 Phase 4 potassium citrate
35 The P.O.W.E.R. STUDY (Premenopause, Osteopenia/Osteoporosis, Women, Alendronate, Depression) Completed NCT00006180 Phase 4 Alendronate
36 Treatment of Vitamin D Insufficiency Completed NCT00933244 Phase 4
37 Is Dietary Melatonin Supplementation a Viable Adjunctive Therapy for Chronic Periodontitis? A Preliminary Randomized Clinical Trial. Completed NCT03368430 Phase 4 Placebo
38 Estimation of Interleukin-21 Levels in Gingival Crevicular Fluid in Patients With Periodontal Health and Disease Following Non-surgical Periodontal Therapy: A Clinico-biochemical Study Completed NCT02861937 Phase 4
39 A Method for Measuring Volume Changes of the Alveolar Ridge During Dental Implantation Using 3D Scanning Recruiting NCT03089619 Phase 4 Human-Spongiosa
40 Bone Resorption, Osteoclastogenesis and Adalimumab Recruiting NCT02035800 Phase 4 Adalimumab
41 Department of Orthopedics, National Taiwan University Hospital Recruiting NCT03868033 Phase 4 Zoledronic Acid;Denosumab
42 The Use of Intranasal Calcitonin to Improve Pain and Activity in Elderly Pelvic Ring Injuries Recruiting NCT03812991 Phase 4 Miacalcin Calcitonin Salmon Nasal Spray
43 The Efficacy of Denosumab to Prevent Bone Loss in Ambulatory and Non-ambulatory Motor-Incomplete Patients With Subacute Spinal Cord Injury Recruiting NCT03029442 Phase 4 Denosumab (Prolia)
44 Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism Recruiting NCT03887936 Phase 4 Testosterone gel 1.62%;Placebo
45 Novel Combination Therapy for Osteoporosis in Men Recruiting NCT03994172 Phase 4 Teriparatide or human parathyroid hormone (PTH) 1-34;Cinacalcet;placebo tablet
46 Treatment With Zoledronic Acid Subsequent to Denosumab in Osteoporosis Active, not recruiting NCT03087851 Phase 4 Zoledronic Acid
47 Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery Not yet recruiting NCT04087096 Phase 4 Denosumab;Placebo;Zoledronic Acid
48 The Effect Of Hyaluronic Acid And Melatonin With Systemic Administration of Vitamin C On Implant Stability After Immediate Implant Placement in Anterior and Premolar Region in Systemically Healthy Patients Not yet recruiting NCT03804177 Phase 4
49 The Effect of Hyaluronic Acid on Implant Stability After Immediate Implant Placement in Anterior and Premolar Region in Systemically Healthy Patients Not yet recruiting NCT03691467 Phase 4 Hyaluronic Acid
50 Clinical Evaluation of Topical Melatonin Application on Implant Stability of Immediate Dental Implant in Anterior & Premolar Region in Systemically Healthy Patients (Randomized Clinical Trial) Not yet recruiting NCT03689998 Phase 4

Search NIH Clinical Center for Bone Resorption Disease

Cochrane evidence based reviews: bone resorption

Genetic Tests for Bone Resorption Disease

Anatomical Context for Bone Resorption Disease

MalaCards organs/tissues related to Bone Resorption Disease:

40
Bone, Breast, Bone Marrow, Prostate, Monocytes, T Cells, Kidney

Publications for Bone Resorption Disease

Articles related to Bone Resorption Disease:

(show top 50) (show all 24415)
# Title Authors PMID Year
1
Aspirin inhibits osteoclast formation and wear-debris-induced bone destruction by suppressing mitogen-activated protein kinases. 61
31498438 2020
2
Antiosteoclastic bone resorption activity of osteoprotegerin via enhanced AKT/mTOR/ULK1-mediated autophagic pathway. 61
31535378 2020
3
Janus kinase inhibitors role in bone remodeling. 61
31486093 2020
4
RANKL triggers resistance to TRAIL-induced cell death in oral squamous cell carcinoma. 61
31309556 2020
5
Urinary cross-linked carboxyterminal telopeptide, a bone resorption marker, decreases after vaso-occlusive crises in adults with sickle cell disease. 61
31677454 2020
6
Metabolomics analysis in adults with high bone mass identifies a relationship between bone resorption and circulating citrate which replicates in the general population. 61
31667854 2020
7
Effect of bisphosphonate on the prevention of bone loss in patients with gastric cancer after gastrectomy: A randomized controlled trial. 61
31706052 2020
8
Synergistic combination treatment to break cross talk between cancer cells and bone cells to inhibit progression of bone metastasis. 61
31654872 2020
9
Alendronate inhibits osteocyte apoptosis and inflammation via IL-6, inhibiting bone resorption in periapical lesions of ovariectomized rats. 61
31429089 2020
10
Catalpol suppresses osteoclastogenesis and attenuates osteoclast-derived bone resorption by modulating PTEN activity. 61
31751538 2020
11
Hematopoietic stem cell transplantation-induced bone remodeling in autosomal recessive osteopetrosis: Interaction between skeleton and hematopoietic and sensory nervous systems. 61
31706050 2020
12
Cellular study of the LPS-induced osteoclastic multinucleated cell formation from RAW264.7 cells. 61
31222739 2020
13
Intracanal Metformin Promotes Healing of Apical Periodontitis via Suppressing Inducible Nitric Oxide Synthase Expression and Monocyte Recruitment. 61
31753516 2020
14
LncRNA expression profiles and the negative regulation of lncRNA-NOMMUT037835.2 in osteoclastogenesis. 61
31593824 2020
15
Histone deacetylases 1 and 2 inhibition suppresses cytokine production and osteoclast bone resorption in vitro. 61
31222845 2020
16
Dissecting the mechanisms of bone loss in Gorham-Stout disease. 61
31525474 2020
17
GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH2. 61
31622777 2020
18
Blocking glucocorticoid signaling in osteoblasts and osteocytes prevents mechanical unloading-induced cortical bone loss. 61
31704341 2020
19
Radiological diagnostic features of uremic leontiasis ossea: a case report. 61
31559846 2020
20
Clinical Considerations on Strategies That Avoid Multiple Connections and Disconnections of Implant Abutments. 61
31815968 2020
21
Extracellular Ca2+ in Bone Marrow. 61
31646545 2020
22
Hippuric acid and 3-(3-hydroxyphenyl) propionic acid inhibit murine osteoclastogenesis through RANKL-RANK independent pathway. 61
31271661 2020
23
Global deletion of Optineurin results in altered type I IFN signaling and abnormal bone remodeling in a model of Paget's disease. 61
31076632 2020
24
Comparative prospective study on the presentation of normocalcemic primary hyperparathyroidism. Is it more aggressive than the hypercalcemic form? 61
31662196 2020
25
Proteasome inhibition suppress microgravity elevated RANK signaling during osteoclast differentiation. 61
31470364 2020
26
Protocatechuic acid attenuates anterior cruciate ligament transection-induced osteoarthritis by suppressing osteoclastogenesis. 61
31853294 2020
27
High LDL levels lessen bone destruction during antigen-induced arthritis by inhibiting osteoclast formation and function. 61
31712132 2020
28
Oleanolic acid exerts inhibitory effects on the late stage of osteoclastogenesis and prevents bone loss in osteoprotegerin knockout mice. 61
31318102 2020
29
The multiple faces of tryptophan in bone biology. 61
31705966 2020
30
The Nrf2 activator RTA-408 attenuates osteoclastogenesis by inhibiting STING dependent NF-κb signaling. 61
31487581 2020
31
Zinc supplements and bone health: The role of the RANKL-RANK axis as a therapeutic target. 61
31653549 2020
32
Zoledronate rescues immunosuppressed monocytes in sepsis patients. 61
31606902 2020
33
A novel regulatory role of TRAPPC9 in L-plastin-mediated osteoclast actin ring formation. 61
31453638 2020
34
First clinical application of octacalcium phosphate collagen composite on bone regeneration in maxillary sinus floor augmentation: A prospective, single-arm, open-label clinical trial. 61
30980703 2020
35
Ectopic osteogenesis by type I collagen loaded with a novel synthesized PTH-related peptide-1 in vivo. 61
31581365 2020
36
Role of the captured retroviral envelope syncytin-B gene in the fusion of osteoclast and giant cell precursors and in bone resorption, analyzed ex vivo and in vivo in syncytin-B knockout mice. 61
31360740 2019
37
A Novel, Tumor-Induced Osteoclastogenesis Pathway Insensitive to Denosumab but Interfered by Cannabidiol. 61
31835378 2019
38
Abaloparatide at the same dose has the same effects on bone as PTH (1-34) in mice. 61
31793033 2019
39
Inhibition of osteoclastogenesis by the RNA-binding protein QKI5: a novel approach to protect from bone resorption. 61
31834954 2019
40
Statistical analysis of implant and thread parameters effects on dental implant stability and bone resorption using central composite design method. 61
31617814 2019
41
A bone resorption marker as predictor of rate of change in femoral neck size and strength during the menopause transition. 61
31473793 2019
42
Multiple brain abscesses treated by extraction of the maxillary molars with chronic apical lesion to remove the source of infection. 61
31321221 2019
43
The Role of NF-κB in Physiological Bone Development and Inflammatory Bone Diseases: Is NF-κB Inhibition "Killing Two Birds with One Stone"? 61
31847314 2019
44
Astilbin prevents bone loss in ovariectomized mice through the inhibition of RANKL-induced osteoclastogenesis. 61
31603626 2019
45
What Is the Role of Interleukins in Breast Cancer Bone Metastases? A Systematic Review of Preclinical and Clinical Evidence. 61
31847214 2019
46
Clinical value of serum bone resorption markers for predicting clinical outcomes after use of bone modifying agents in metastatic bone tumors: a prospective cohort study. 61
31846063 2019
47
Two novel peptides from ark shell protein stimulate osteoblast differentiation and rescue ovariectomy-induced bone loss. 61
31697996 2019
48
Synergistic alveolar bone resorption by diabetic advanced glycation end products and mechanical forces. 61
31294467 2019
49
Effects of prostaglandin E2 and D2 on cell proliferation and osteogenic capacity of human mesenchymal stem cells. 61
31589940 2019
50
miR-409-5p negatively regulates Wnt/Beta catenin signaling pathway by targeting Lrp-8. 61
31165485 2019

Variations for Bone Resorption Disease

Expression for Bone Resorption Disease

Search GEO for disease gene expression data for Bone Resorption Disease.

Pathways for Bone Resorption Disease

GO Terms for Bone Resorption Disease

Cellular components related to Bone Resorption Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 TNFSF11 TNFRSF11B SOST PTH IGF1 CTSK
2 extracellular space GO:0005615 9.4 TNFSF11 TNFRSF11B SOST PTH MIR335 MIR140

Biological processes related to Bone Resorption Disease according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.97 VDR TNFSF11 SP7 RUNX2 PTH NFATC1
2 positive regulation of transcription, DNA-templated GO:0045893 9.95 SOST RUNX2 NFATC1 LRP5 IGF1 BMP2
3 gene silencing by miRNA GO:0035195 9.85 MIR214 MIR188 MIR140 MIR133A1
4 positive regulation of gene expression GO:0010628 9.8 VDR TNFSF11 RUNX2 MIR140 MIR133A1 IGF1
5 osteoblast differentiation GO:0001649 9.73 SP7 RUNX2 BMP2 BGLAP
6 negative regulation of tumor necrosis factor production GO:0032720 9.7 MIR140 IGF1 ACP5
7 positive regulation of osteoblast differentiation GO:0045669 9.67 RUNX2 LRP5 IGF1 BMP2
8 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.63 MIR214 MIR140 MIR133A1
9 response to vitamin D GO:0033280 9.61 PTH BGLAP
10 positive regulation of glycogen biosynthetic process GO:0045725 9.6 PTH IGF1
11 negative regulation of interleukin-1 beta production GO:0032691 9.59 IGF1 ACP5
12 positive regulation of ossification GO:0045778 9.58 PTH BMP2
13 regulation of osteoclast differentiation GO:0045670 9.58 TNFSF11 BGLAP
14 osteoblast development GO:0002076 9.58 RUNX2 LRP5 BGLAP
15 negative regulation of bone resorption GO:0045779 9.57 TNFRSF11B CALCA
16 response to inorganic substance GO:0010035 9.56 TNFRSF11B BGLAP
17 positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus GO:1901522 9.54 RUNX2 BMP2
18 regulation of odontogenesis of dentin-containing tooth GO:0042487 9.51 RUNX2 BMP2
19 bone mineralization involved in bone maturation GO:0035630 9.49 IGF1 BMP2
20 bone resorption GO:0045453 9.46 TNFSF11 PTH CTSK ACP5
21 ossification GO:0001503 9.43 TNFSF11 SOST RUNX2 BMP2 BGLAP ACP5
22 skeletal system development GO:0001501 9.17 VDR TNFRSF11B RUNX2 PTH IGF1 BMP2

Molecular functions related to Bone Resorption Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.13 PTH IGF1 CALCA
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 8.92 MIR214 MIR188 MIR140 MIR133A1

Sources for Bone Resorption Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....